| Working Paper |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| Aging and the Growth of Long-Term Care |
1 |
2 |
2 |
2 |
3 |
7 |
9 |
9 |
| Aging and the Growth of Long-Term Care |
1 |
5 |
18 |
198 |
16 |
38 |
101 |
1,055 |
| An Empirical Examination of Information Barriers to Trade in Insurance |
6 |
7 |
50 |
304 |
14 |
50 |
236 |
1,910 |
| An Empirical Examination of Information Barriers to Trade inInsurance |
0 |
0 |
0 |
0 |
1 |
4 |
34 |
868 |
| Antitrust and the Not-For-Profit Sector |
1 |
4 |
18 |
253 |
10 |
27 |
79 |
763 |
| Antitrust in the Not-For-Profit Sector |
1 |
2 |
16 |
93 |
11 |
19 |
71 |
290 |
| Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process |
1 |
5 |
16 |
71 |
7 |
20 |
67 |
345 |
| Assessing the Safety and Efficacy of the FDA: The Case of the Prescription Drug User Fee Acts |
1 |
1 |
3 |
64 |
5 |
15 |
33 |
180 |
| Consumption vs. Production of Insurance |
0 |
0 |
2 |
103 |
3 |
5 |
17 |
717 |
| Data MArkets and OPtimal Sample Size Determination |
0 |
0 |
0 |
0 |
4 |
10 |
42 |
2,696 |
| Death, Tetanus and Aerobics: The Evaluation of Disease-Specific Health Interventions |
1 |
1 |
5 |
43 |
3 |
9 |
39 |
346 |
| Death, Tetanus, and Aerobics: The Evaluation of Disease-Specific Health Interventions |
0 |
0 |
2 |
2 |
0 |
1 |
6 |
63 |
| Disease Complementarities and the Evaluation of Public Health Interventions |
1 |
1 |
9 |
105 |
2 |
4 |
19 |
834 |
| Disease Eradication: Private vs. Public Vaccination |
0 |
0 |
0 |
0 |
3 |
8 |
26 |
380 |
| Economic Epidemiology and Infectious Diseases |
1 |
16 |
113 |
606 |
11 |
53 |
295 |
1,871 |
| Endogenous Cost-Effectiveness Analysis in Health Care Technology Adoption |
6 |
10 |
19 |
19 |
9 |
23 |
51 |
51 |
| Estimating the Extent of Trade Under Incomplete Information: The Case of HIV |
0 |
0 |
0 |
0 |
0 |
0 |
6 |
99 |
| External Treatment Effects and Program Implementation Bias |
1 |
1 |
7 |
48 |
6 |
16 |
70 |
314 |
| External Treatment Effects and Program Implementation Bias |
0 |
0 |
0 |
0 |
3 |
3 |
5 |
5 |
| Health Care, Technological Change, and Altruistic Consumption Externalities |
1 |
2 |
4 |
30 |
2 |
18 |
50 |
172 |
| Health Investment Complementarities under Competing Risks |
0 |
0 |
5 |
155 |
1 |
5 |
21 |
991 |
| Integrated Insurance Design in the Presence of Multiple Medical Technologies |
1 |
1 |
4 |
12 |
5 |
9 |
33 |
75 |
| Intellectual Property & External Consumption Effects: Generalizations from Pharmaceutical Markets |
2 |
4 |
7 |
140 |
2 |
10 |
31 |
431 |
| Intellectual Property and Marketing |
3 |
6 |
13 |
65 |
5 |
10 |
43 |
211 |
| Is Health Care Technology Over-Approved? A Meta-Analysis of Revealed Preference |
0 |
0 |
0 |
0 |
1 |
2 |
5 |
150 |
| Is the Food and Drug Administration Safe and Effective? |
2 |
5 |
17 |
54 |
9 |
17 |
57 |
155 |
| Is the Obesity Epidemic a Public Health Problem? A Decade of Research on the Economics of Obesity |
9 |
26 |
104 |
183 |
27 |
74 |
269 |
429 |
| Merit Motives and Government Intervention: Public Finance in Reverse |
0 |
0 |
9 |
190 |
2 |
9 |
38 |
765 |
| Merit Motives and Government Intervention: Public Finance in Reverse |
0 |
1 |
6 |
99 |
12 |
26 |
84 |
789 |
| Mortality Contingent Claims, Health Care, and Social Insurance |
0 |
0 |
0 |
0 |
3 |
6 |
26 |
1,035 |
| Mortality Contingent Claims, Health Care, and Social Insurance |
0 |
1 |
5 |
126 |
1 |
5 |
29 |
465 |
| Nonprofit Production |
0 |
0 |
0 |
0 |
0 |
3 |
14 |
142 |
| Nonprofit Production and Competition |
0 |
1 |
10 |
258 |
3 |
11 |
48 |
1,100 |
| Observational Agency and Supply-Side Econometrics |
0 |
0 |
0 |
24 |
3 |
4 |
14 |
336 |
| Pricing and R&D with Related Margins |
0 |
0 |
0 |
0 |
2 |
4 |
22 |
493 |
| Rational Epidemics and their Public Control |
0 |
0 |
0 |
0 |
6 |
14 |
59 |
387 |
| Self-Interested Treatment Evaluation in Experiments |
0 |
0 |
0 |
0 |
1 |
2 |
9 |
87 |
| Surplus Appropriation from R&D and Health Care Technology Assessment Procedures |
1 |
4 |
15 |
85 |
9 |
22 |
103 |
390 |
| Surplus Appropriation from R&D and Health Care Technology Assessment Procedures |
4 |
6 |
17 |
51 |
8 |
17 |
51 |
199 |
| The Dual Effects of Intellectual Property Regulations: Within- and Between- Patent Competition in the US Pharmaceuticals Industry |
0 |
1 |
13 |
244 |
0 |
11 |
68 |
653 |
| The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the US |
0 |
0 |
5 |
6 |
1 |
4 |
19 |
21 |
| The Future of Old-Age Longevity: Competitive Pricing of Morality Contingent Claims |
0 |
0 |
0 |
0 |
0 |
2 |
24 |
932 |
| The Future of Old-Age Longevity: Competitive Pricing of Mortality Contingent Claims |
1 |
3 |
11 |
61 |
2 |
6 |
39 |
282 |
| The Growth of Obesity and Technological Change: A Theoretical and Empirical Examination |
2 |
10 |
34 |
318 |
9 |
29 |
95 |
911 |
| The Growth of Obesity and Technological Change: A Theoretical and Empirical Examination |
1 |
7 |
28 |
29 |
8 |
20 |
74 |
75 |
| The Long-Run Growth in Obesity as a Function of Technological Change |
0 |
3 |
21 |
416 |
4 |
10 |
75 |
1,765 |
| The Long-Run Growth in Obesity as a Function of Technological Change |
1 |
4 |
8 |
8 |
5 |
9 |
14 |
14 |
| The Private Demand for Information and the Effects of Public Testing Programs: The Case of HIV |
0 |
0 |
0 |
0 |
0 |
2 |
9 |
377 |
| The Quantity and Quality of Life and the Evolution of World Inequality |
7 |
12 |
44 |
596 |
19 |
39 |
152 |
1,622 |
| The Rise in Old Age Longevity and the Market for Long-Term Care |
0 |
0 |
0 |
0 |
2 |
8 |
31 |
648 |
| The Rise in Old Age Longevity and the Market for Long-Term Care |
2 |
3 |
19 |
192 |
11 |
23 |
98 |
1,527 |
| The Value of Life Near its End and Terminal Care |
4 |
11 |
48 |
159 |
11 |
27 |
142 |
343 |
| The Value of Life Near its End and Terminal Care |
4 |
9 |
40 |
111 |
9 |
19 |
80 |
190 |
| The Value of Life in General Equilibrium |
1 |
7 |
24 |
55 |
2 |
15 |
81 |
140 |
| Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS Drugs |
2 |
8 |
16 |
89 |
11 |
26 |
80 |
283 |
| Will the AIDS Epidemic be Self-Limiting? Evidence on the Responsiveness of the Demand for Condoms to the Prevalence of AIDS |
2 |
3 |
5 |
5 |
2 |
3 |
5 |
5 |
| Will the AIDS Epidemic be Self-Limiting? Evidence on the Responsiveness of the Demand for Condoms to the Prevalence of AIDS |
0 |
0 |
0 |
1 |
0 |
2 |
15 |
193 |
| Total Working Papers |
72 |
193 |
812 |
5,673 |
309 |
835 |
3,313 |
31,579 |